Nuva Ring PATIENT EDUCATION SERIES
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Preven Emergency Contraceptive
9/1/1998 1 Rx Only PREVENÔ Emergency Contraceptive Kit consisting of Emergency Contraceptive Pills and Pregnancy Test Emergency Contraceptive Pills (Levonorgestrel and Ethinyl Estradiol Tablets, USP) and Pregnancy Test The PREVENÔ Emergency Contraceptive Kit is intended to prevent pregnancy after known or suspected contraceptive failure or unprotected intercourse. Emergency contraceptive pills (like all oral contraceptives) do not protect against infection with HIV (the virus that causes AIDS) and other sexually transmitted diseases. DESCRIPTION The PREVENÔ Emergency Contraceptive Kit consists of a patient information book, a urine pregnancy test and four (4) emergency contraceptive pills (ECPs). The pills in the PREVENÔ Emergency Contraceptive Kit are combination oral contraceptives (COCs) which are used to provide postcoital emergency contraception. Each blue film-coated pill contains 0.25 mg levonorgestrel (18,19-Dinorpregn-4-en-20- yn-3-one, 13-Ethyl-17-hydroxy-, (17a)-(-), a totally synthetic progestogen, and 0.05 mg ethinyl estradiol (19-Nor-17a-pregna-1,3,5, (10)-trien-20-yne-3,17-diol). The inactive ingredients present are polacrilin potassium, lactose, magnesium stearate, hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol, polysorbate 80 and FD&C Blue No.2 Aluminum Lake. MOLECULES TO BE ADDED The Pregnancy Test uses monoclonal antibodies to detect the presence of hCG (Human Chorionic Gonadotropin) in the urine. It is sensitive to 20 – 25 mIU / mL 9/1/1998 2 CLINICAL PHARMACOLOGY ECPs are not effective if the woman is pregnant; they act primarily by inhibiting ovulation. They may also act by altering tubal transport of sperm and/or ova (thereby inhibiting fertilization), and/or possibly altering the endometrium (thereby inhibiting implantation). -
Which Contraceptive Is Right for You?
IT’S NOT A MATTER OF LUCK! WHICH CONTRACEPTIVE IS RIGHT FOR YOU? @FIUHLP FIU Healthy @FIUHLP FIUHLP @FIUHLPRD Living Program BEFORE YOU GET BUSY…. Prescription/ Can Be Used Pregnancy Doctor’s Protects Contraception Ahead of Time Prevention Visit Need Against STI’s Key Hormonal Available at SHC The N/A Pill/Patch/Ring 90% Yes No N/A Hormonal IUD 99% Yes No N/A Implant 99% Yes No The Shot N/A 99% Yes No Non-Hormonal No Male Condoms 80% No Yes Female Yes Condoms 80% No Yes N/A Copper IUD 99% Yes No Yes Diaphragm 90% Yes No No Spermicide 70% No No Fertility Yes Awareness 75% No No *Pregnancy and STI prevention Sterilization N/A Almost 100% Yes No depends on personal consistent N/A Withdrawal 70% No No Yes and correct use.* Abstinence 100% No Yes Hormonal Spermicide The Pill/Patch/Ring Kills sperm Available in jelly, foam, cream, suppositories, and film Release hormones to inhibit the body’s natural Spermicide must be reapplied every time before sex cyclical hormones to help prevent pregnancy Provides poor protection against pregnancy itself - more Suppress ovulation, thicken the cervical mucus, and effective when used with a barrier method thin the lining of the womb • The Pill must be taken daily. Cervical Cap • The Patch must be replaced weekly. Treated with spermicide • The Ring can be worn for 3 weeks. Can be inserted before sex, and must be left in place 6 hours afterward Hormonal IUD Spermicide must be reapplied every time before sex Requires a doctor’s visit for fitting and another to ensure correct use Thickens cervical mucus and -
Reseptregisteret 2013–2017 the Norwegian Prescription Database
LEGEMIDDELSTATISTIKK 2018:2 Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Christian Berg Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Utgitt av Folkehelseinstituttet/Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2018 Tittel/Title: Legemiddelstatistikk 2018:2 Reseptregisteret 2013–2017 / The Norwegian Prescription Database 2013–2017 Forfattere/Authors: Christian Berg, redaktør/editor Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon/Contact information: Folkehelseinstituttet/Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8082-926-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2013–2017 [The Norwegian Prescription Database 2013–2017] Legemiddelstatistikk 2018:2, Oslo, Norge: Folkehelseinstituttet, 2018. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian Prescription Database 2005–2009. -
Plan C: Copper IUD As Emergency Contraception IMPLEMENTATION TOOLKIT for Administrators and Clinicians
Plan C: Copper IUD as Emergency Contraception IMPLEMENTATION TOOLKIT for Administrators and Clinicians March 2016 Developed by TABLE OF CONTENTS SECTION 1: OVERVIEW ● Introduction Page 1 ● Background Page 2 ● Who It’s For Page 3 ● How to Use It Page 4 ● Additional Considerations Page 5 SECTION 2: ADMINISTRATIVE ● Pre-Implementation Tools Page 6 1.1 Overview: Plan C 1.2 Checklist: Pre-Implementation 1.3 Staff Buy-in 1.4 Checklist: Policies and Procedures 1.5 Sample: Policies and Procedures 1.6 Marketing Plan C 1.7 Sample: Data Collection Tool SECTION 3: CLINICAL ● Implementation Tools Page 21 2.1 The Facts: The Copper-T as Plan C 2.2 Sample: EC Screening Questionnaire 2.3 Triage Scripts 2.4 Contraceptive Counseling 2.5 Eligibility Flowchart: Plan C 2.6 Checklist: Exam Room Preparation 2.7 Checklist: Client-Centered Approach 2.8 Fact Sheet: Copper IUD Aftercare 2.9 Side Effects Management: Steps in the Delivery of Care 2.10 Side Effects Management: Messages, Assessment & Treatment SECTION 4: ADDITIONAL RESOURCES ● Client Education Material: F.A.Q.’s Page 40 ● Client Education Material: EC Chart Page 42 SECTION 5: REFERENCES Page 44 OVERVIEW Introduction The New York State Center of Excellence for Family Planning and Reproductive Health Services (NYS COE) developed this toolkit to support agencies that receive Title X family planning funding through the New York State Department of Health (NYS DOH) Comprehensive Family Planning and Reproductive Health Care Services Program – as well as other sexual and reproductive health service providers – to implement Plan C: Copper IUD as Emergency Contraception (Plan C). -
Mycophenolate: OB-GYN Contraception Counseling Referral
Current as of 6/1/2013. This document may not be part of the latest approved REMS. OB/GYN CONTRACEPTION COUNSELING LETTER Reference ID: 3194413 Current as of 6/1/2013. This document may not be part of the latest approved REMS. Letter to Ob/Gyn Contraception Counseling ((Date)) ((Recipient’s Name)) ((Recipient’s Address 1)) ((Recipient’s Address 2)) ((City, State, ZIP)) In reference to: My patient ((Patient’s Name)) Reason for the referral: Contraception counseling Dear Dr ((Recipient’s Last Name)): I am writing to you in reference to the above-named patient who is under my care for ((diagnosis)) and ((insert drug information such as drug name, when patient will begin taking the drug, if treatment has already begun, etc)). This medication contains mycophenolate, which is associated with an increased risk of first trimester pregnancy loss and congenital malformations. It is important that this patient receive contraception counseling about methods that are acceptable for use while taking mycophenolate. Prescribers of mycophenolate participate in the FDA-mandated Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) to ensure that the benefits of mycophenolate outweigh the risks. The following table lists the forms of contraception that are acceptable for use during treatment with mycophenolate. Acceptable Contraception Methods for Females of Reproductive Potential Guide your patients to choose from the following birth control options: Option 1 Intrauterine devices (IUDs) Tubal sterilization Methods to Use Patient’s partner had -
New Insights Into Human Female Reproductive Tract Development
UCSF UC San Francisco Previously Published Works Title New insights into human female reproductive tract development. Permalink https://escholarship.org/uc/item/7pm5800b Journal Differentiation; research in biological diversity, 97 ISSN 0301-4681 Authors Robboy, Stanley J Kurita, Takeshi Baskin, Laurence et al. Publication Date 2017-09-01 DOI 10.1016/j.diff.2017.08.002 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Differentiation 97 (2017) xxx–xxx Contents lists available at ScienceDirect Differentiation journal homepage: www.elsevier.com/locate/diff New insights into human female reproductive tract development MARK ⁎ Stanley J. Robboya, , Takeshi Kuritab, Laurence Baskinc, Gerald R. Cunhac a Department of Pathology, Duke University, Davison Building, Box 3712, Durham, NC 27710, United States b Department of Cancer Biology and Genetics, The Comprehensive Cancer Center, Ohio State University, 460 W. 12th Avenue, 812 Biomedical Research Tower, Columbus, OH 43210, United States c Department of Urology, University of California, 400 Parnassus Avenue, San Francisco, CA 94143, United States ARTICLE INFO ABSTRACT Keywords: We present a detailed review of the embryonic and fetal development of the human female reproductive tract Human Müllerian duct utilizing specimens from the 5th through the 22nd gestational week. Hematoxylin and eosin (H & E) as well as Urogenital sinus immunohistochemical stains were used to study the development of the human uterine tube, endometrium, Uterovaginal canal myometrium, uterine cervix and vagina. Our study revisits and updates the classical reports of Koff (1933) and Uterus Bulmer (1957) and presents new data on development of human vaginal epithelium. Koff proposed that the Cervix upper 4/5ths of the vagina is derived from Müllerian epithelium and the lower 1/5th derived from urogenital Vagina sinus epithelium, while Bulmer proposed that vaginal epithelium derives solely from urogenital sinus epithelium. -
Delaying Menstruation During Holidays. Norethisterone 5Mg Tds
Delaying menstruation during holidays. Norethisterone 5mg tds, started 3 days before the expected menses can be used for the postponement of menstruation and is often prescribed prior to a holiday. The effectiveness of the delay varies between individuals. So what is the problem? A review article in the Journal of Family Planning and Reproductive healthcare ( Mansour 2012) highlighted that owing to the specific structure of norethisterone, it is partly metabolised to ethinyl oestradiol. Chu et al 2007 suggested that a daily dose of norethisterone 5mg tds might be equivalent to taking 20-30mcg combined oral contraceptive pill. Therefore, prescribing therapeutic doses of norethisterone for women with significant risk factors for venous thromboembolism ( VTE) may therefore be inappropriate. Who shouldn’t be given norethisterone? Obese Personal h/o VTE Strong FH of VTE Immobile/wheelchair bound Carriers of thrombophilia Any other condition predisposing to VTE If my patient can’t take norethisterone, what are the alternatives? The metabolism to ethinyl oestradiol occurs with doses of norethisterone 5mg and over and therefore, the concern does not apply to or other progestogens or contraceptive pills containing norethisterone. Mansour suggested Medroxyprogesterone ( MPA ) 10mg three times a day to reduce heavy menstrual bleeding. Dr Sarah Grey (personal communication) recommends 20mg medroxyprogesterone to be taken daily, starting 3 days before the expected onset of menses. However, (MPA) is not licensed for this use and the prescriber should follow the rules of off label prescribing. References Safer prescribing of therapeutic norethisterone for women at risk of venous thromboembolism. Mansour JFPRHC July 2012 Formation of ethinyl oestradiol in women during treatment with norethisterone acetate. -
U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 65 / No. 3 July 29, 2016 U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................2 How to Use This Document ...............................................................................3 Keeping Guidance Up to Date ..........................................................................5 References ................................................................................................................8 Abbreviations and Acronyms ............................................................................9 Appendix A: Summary of Changes from U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 ...........................................................................10 Appendix B: Classifications for Intrauterine Devices ............................. 18 Appendix C: Classifications for Progestin-Only Contraceptives ........ 35 Appendix D: Classifications for Combined Hormonal Contraceptives .... 55 Appendix E: Classifications for Barrier Methods ..................................... 81 Appendix F: Classifications for Fertility Awareness–Based Methods ..... 88 Appendix G: Lactational -
Vaginal Administration of Contraceptives
Scientia Pharmaceutica Review Vaginal Administration of Contraceptives Esmat Jalalvandi 1,*, Hafez Jafari 2 , Christiani A. Amorim 3 , Denise Freitas Siqueira Petri 4 , Lei Nie 5,* and Amin Shavandi 2,* 1 School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK 2 BioMatter Unit, École Polytechnique de Bruxelles, Université Libre de Bruxelles, Avenue F.D. Roosevelt, 50-CP 165/61, 1050 Brussels, Belgium; [email protected] 3 Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, 1200 Brussels, Belgium; [email protected] 4 Fundamental Chemistry Department, Institute of Chemistry, University of São Paulo, Av. Prof. Lineu Prestes 748, São Paulo 05508-000, Brazil; [email protected] 5 College of Life Sciences, Xinyang Normal University, Xinyang 464000, China * Correspondence: [email protected] (E.J.); [email protected] (L.N.); [email protected] (A.S.); Tel.: +32-2-650-3681 (A.S.) Abstract: While contraceptive drugs have enabled many people to decide when they want to have a baby, more than 100 million unintended pregnancies each year in the world may indicate the contraceptive requirement of many people has not been well addressed yet. The vagina is a well- established and practical route for the delivery of various pharmacological molecules, including contraceptives. This review aims to present an overview of different contraceptive methods focusing on the vaginal route of delivery for contraceptives, including current developments, discussing the potentials and limitations of the modern methods, designs, and how well each method performs for delivering the contraceptives and preventing pregnancy. -
Recommendations for Contraceptive Use, 2013 Adapted from the World Health Organization Selected Practice Recommendations for Contraceptive Use, 2Nd Edition
Morbidity and Mortality Weekly Report Early Release / Vol. 62 June 14, 2013 U.S. Selected Practice Recommendations for Contraceptive Use, 2013 Adapted from the World Health Organization Selected Practice Recommendations for Contraceptive Use, 2nd Edition Continuing Education Examination available at http://www.cdc.gov/mmwr/cme/conted.html. U.S. Department of Health and Human Services Centers for Disease Control and Prevention Early Release CONTENTS CONTENTS (Continued) Introduction ............................................................................................................1 Appendix A: Summary Chart of U.S. Medical Eligibility Criteria for Methods ....................................................................................................................2 Contraceptive Use, 2010 .................................................................................. 47 How To Use This Document ...............................................................................3 Appendix B: When To Start Using Specific Contraceptive Summary of Changes from WHO SPR ............................................................4 Methods .............................................................................................................. 55 Contraceptive Method Choice .........................................................................4 Appendix C: Examinations and Tests Needed Before Initiation of Maintaining Updated Guidance ......................................................................4 Contraceptive Methods -
Cervical Ectropion May Be a Cause of Desquamative Inflammatory Vaginitis. Leia Mitchell
Himmelfarb Health Sciences Library, The George Washington University Health Sciences Research Commons Obstetrics and Gynecology Faculty Publications Obstetrics and Gynecology 4-28-2017 Cervical Ectropion May Be a Cause of Desquamative Inflammatory Vaginitis. Leia Mitchell Michelle King Heather Brillhart George Washington University Andrew Goldstein Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_obgyn_facpubs Part of the Obstetrics and Gynecology Commons APA Citation Mitchell, L., King, M., Brillhart, H., & Goldstein, A. (2017). Cervical Ectropion May Be a Cause of Desquamative Inflammatory Vaginitis.. Sexual Medicine, (). http://dx.doi.org/10.1016/j.esxm.2017.03.001 This Journal Article is brought to you for free and open access by the Obstetrics and Gynecology at Health Sciences Research Commons. It has been accepted for inclusion in Obstetrics and Gynecology Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please contact [email protected]. Cervical Ectropion May Be a Cause of Desquamative Inflammatory Vaginitis Leia Mitchell, MSc,1 Michelle King, MSc,1,2 Heather Brillhart, MD,3 and Andrew Goldstein, MD1,3 ABSTRACT Desquamative inflammatory vaginitis is a poorly understood chronic vaginitis with an unknown etiology. Symptoms of desquamative inflammatory vaginitis include copious yellowish discharge, vulvovaginal discomfort, and dyspareunia. Cervical ectropion, the presence of glandular columnar cells on the ectocervix, has not been reported as a cause of desquamative inflammatory vaginitis. Although cervical ectropion can be a normal clinical finding, it has been reported to cause leukorrhea, metrorrhagia, dyspareunia, and vulvovaginal irritation. Patients with cervical ectropion and des- quamative inflammatory vaginitis are frequently misdiagnosed with candidiasis or bacterial vaginosis and repeatedly treated without resolution of symptoms. -
EDUCATION Clinical Challenge
EDUCATION Questions for this month’s clinical challenge are based on articles in this issue. The style and scope of questions is in keeping with the MCQ of the College Fellowship exam. The quiz is endorsed by the RACGP Quality Assurance and Clinical challenge Continuing Professional Development Program and has been allocated 4 CPD points per issue. Answers to this clinical challenge will be published next month, and are available immediately following successful completion online at: www.racgp.org.au/clinicalchallenge. Jenni Parsons SINGLE COMPLETION ITEMS DIRECTIONS Each of the questions or incomplete statements below is followed by five suggested answers or completions. Select the most appropriate statement as your answer. Case 1 – Donna Watson A. have no treatment until the results of the A. abdominal ultrasound Donna, 23 years of age, has been taking tests come back so that the appropriate B. transvaginal ultrasound the combined oral contraceptive pill antibiotic can be given C. a qualitative urine BHCG (COCP) for many years without problems. B. be treated with azithromycin 1 g stat, doxy- D. a quantitative serum BHCG Over the past 6 weeks she has had cycline 100 mg twice daily for 14 days and E. full blood examination and C reactive protein. intermittent vaginal bleeding on several metronidazole 400 mg twice daily for 14 days days per week despite no missed pills. She Question 6 also noted pain on intercourse during that C. be treated with amoxycillin 500 mg and met- You confirm that Sarah is pregnant. She is time and over the past 2 weeks has had ronidazole 400 mg three times daily haemodynamically stable.